Gentherm (THRM) 10-Q 26 Oct 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Oct. 20, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Trading Symbol	THRM
Entity Registrant Name	GENTHERM INCORPORATED
Entity Central Index Key	0000903129
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		32,796,297
Entity Shell Company	false
Entity File Number	0-21810
Entity Tax Identification Number	95-4318554
Entity Address, Address Line One	21680 Haggerty Road
Entity Address, City or Town	Northville
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48167
City Area Code	248
Local Phone Number	504-0500
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	MI
Document Quarterly Report	true
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, no par value
Document Transition Report	false

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 154,354	$ 153,891
Accounts receivable, net	263,765	247,131
Inventory:
Raw materials	122,919	136,217
Work in process	16,745	17,695
Finished goods	66,192	64,336
Inventory, net	205,856	218,248
Other current assets	76,651	64,597
Total current assets	700,626	683,867
Property and equipment, net	236,660	244,480
Goodwill	100,633	119,774
Other intangible assets, net	66,427	73,933
Operating lease right-of-use assets	27,442	29,945
Deferred income tax assets	73,177	69,840
Other non-current assets	20,632	17,461
Total assets	1,225,597	1,239,300
Current Liabilities:
Accounts payable	213,851	182,225
Current lease liabilities	7,633	7,143
Current maturities of long-term debt	620	2,443
Other current liabilities	90,199	93,814
Total current liabilities	312,303	285,625
Long-term debt, less current maturities	207,302	232,653
Non-current lease liabilities	16,451	20,538
Pension benefit obligation	3,165	3,638
Other non-current liabilities	26,324	24,573
Total liabilities	565,545	567,027
Common Stock:
No par value; 55,000,000 shares authorized 32,795,093 and 33,202,082 issued and outstanding at September 30, 2023 and December 31, 2022, respectively	97,715	122,658
Paid-in capital	5,379	5,447
Accumulated other comprehensive loss	(55,955)	(46,489)
Accumulated earnings	612,913	590,657
Total shareholders’ equity	660,052	672,273
Total liabilities and shareholders’ equity	$ 1,225,597	$ 1,239,300

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common Stock, par value
Common Stock, shares authorized	55,000,000	55,000,000
Common Stock, shares issued	32,795,093	33,202,082
Common Stock, shares outstanding	32,795,093	33,202,082

Consolidated Condensed Statemen

Consolidated Condensed Statements of Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Product revenues	$ 366,195	$ 332,962	$ 1,102,143	$ 861,334
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of sales	$ 279,985	$ 252,610	$ 846,815	$ 657,492
Gross margin	86,210	80,352	255,328	203,842
Operating expenses:
Net research and development expenses	23,150	22,666	72,991	62,425
Selling, general and administrative expenses	38,220	34,859	113,680	96,109
Impairment of goodwill			19,509
Restructuring expenses	1,099	6	3,412	561
Total operating expenses	62,469	57,531	209,592	159,095
Operating income	23,741	22,821	45,736	44,747
Interest (expense) income, net	(3,368)	714	(9,444)	(1,285)
Foreign currency gain (loss)	2,107	(8,285)	384	(1,516)
Other income	272	361	1,058	698
Earnings before income tax	22,752	15,611	37,734	42,644
Income tax expense	6,908	5,784	15,478	13,998
Net income	$ 15,844	$ 9,827	$ 22,256	$ 28,646
Basic earnings per share	$ 0.48	$ 0.30	$ 0.67	$ 0.87
Diluted earnings per share	$ 0.48	$ 0.29	$ 0.67	$ 0.86
Weighted average number of shares – basic	32,944,386	33,162,181	33,049,097	33,105,854
Weighted average number of shares – diluted	33,196,000	33,470,439	33,310,601	33,459,750

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 15,844	$ 9,827	$ 22,256	$ 28,646
Other comprehensive loss:
Pension benefit obligations	4	6	12	62
Foreign currency translation adjustments	(16,456)	(28,682)	(11,789)	(60,676)
Unrealized (loss) gain on foreign currency derivative securities, net of tax	(2,090)	1,273	2,311	1,490
Unrealized loss on commodity derivative securities, net of tax				(5)
Other comprehensive loss, net of tax	(18,542)	(27,403)	(9,466)	(59,129)
Comprehensive (loss) income	$ (2,698)	$ (17,576)	$ 12,790	$ (30,483)

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Activities:
Net income	$ 22,256	$ 28,646
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	38,531	30,470
Deferred income taxes	(3,017)	(1,207)
Stock based compensation	8,451	3,383
Loss on disposition of property and equipment	873	620
Provisions for inventory	6,597	4,293
Impairment of goodwill	19,509
Other	81	881
Changes in assets and liabilities:
Accounts receivable, net	(19,813)	(55,780)
Inventory	3,733	(53,223)
Other assets	(19,218)	(10,868)
Accounts payable	32,158	60,983
Other liabilities	(10,099)	4,759
Net cash provided by operating activities	80,042	12,957
Investing Activities:
Purchases of property and equipment	(26,526)	(25,737)
Proceeds from the sale of property and equipment	72	175
Acquisition of businesses, net of cash acquired		(224,097)
Proceeds from deferred purchase price of factored receivables	10,139	2,168
Cost of technology investments	(630)	(350)
Net cash used in investing activities	(16,945)	(247,841)
Financing Activities:
Borrowings on debt		207,000
Repayments of debt	(27,166)	(11,559)
Proceeds from the exercise of Common Stock options	263	1,556
Taxes withheld and paid on employees' share-based payment awards	(2,754)	(5,415)
Cash paid for the repurchase of Common Stock	(31,094)
Net cash (used in) provided by financing activities	(60,751)	191,582
Foreign currency effect	(1,883)	(8,141)
Net cash increase (decrease) in cash and cash equivalents	463	(51,443)
Cash and cash equivalents at beginning of period	153,891	190,606
Cash and cash equivalents at end of period	154,354	139,163
Supplemental disclosure of cash flow information:
Cash paid for taxes	18,893	13,509
Cash paid for interest	9,737	3,334
Non-Cash Investing Activities:
Period-end balance of accounts payable for property and equipment	4,501	2,848
Deferred purchase price of receivables factored in the period	$ 11,344	$ 2,801

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Changes In Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Earnings
Beginning Balance at Dec. 31, 2021	$ 653,806	$ 118,646	$ 5,866	$ (36,922)	$ 566,216
Beginning Balance (in shares) at Dec. 31, 2021		33,008,000
Net (loss) income	11,747				11,747
Other comprehensive income (loss)	(8,806)			(8,806)
Stock compensation, net	(960)	$ (814)	(146)
Stock compensation, net, shares		119,000
Ending Balance at Mar. 31, 2022	655,787	$ 117,832	5,720	(45,728)	577,963
Ending Balance (in shares) at Mar. 31, 2022		33,127,000
Beginning Balance at Dec. 31, 2021	653,806	$ 118,646	5,866	(36,922)	566,216
Beginning Balance (in shares) at Dec. 31, 2021		33,008,000
Net (loss) income	28,646
Other comprehensive income (loss)	(59,129)
Ending Balance at Sep. 30, 2022	624,089	$ 119,801	5,477	(96,051)	594,862
Ending Balance (in shares) at Sep. 30, 2022		33,196,000
Beginning Balance at Mar. 31, 2022	655,787	$ 117,832	5,720	(45,728)	577,963
Beginning Balance (in shares) at Mar. 31, 2022		33,127,000
Net (loss) income	7,072				7,072
Other comprehensive income (loss)	(22,920)			(22,920)
Stock compensation, net	3,256	$ 3,256
Stock compensation, net, shares		6,000
Ending Balance at Jun. 30, 2022	643,195	$ 121,088	5,720	(68,648)	585,035
Ending Balance (in shares) at Jun. 30, 2022		33,133,000
Net (loss) income	9,827				9,827
Other comprehensive income (loss)	(27,403)			(27,403)
Stock compensation, net	(1,530)	$ (1,287)	(243)
Stock compensation, net, shares		63,000
Ending Balance at Sep. 30, 2022	624,089	$ 119,801	5,477	(96,051)	594,862
Ending Balance (in shares) at Sep. 30, 2022		33,196,000
Beginning Balance at Dec. 31, 2022	$ 672,273	$ 122,658	5,447	(46,489)	590,657
Beginning Balance (in shares) at Dec. 31, 2022	33,202,082	33,202,000
Net (loss) income	$ 7,963				7,963
Other comprehensive income (loss)	10,388			10,388
Stock compensation, net	(309)	$ (241)	(68)
Stock compensation, net, shares		94,000
Stock repurchase	(9,997)	$ (9,997)
Stock repurchase (in shares)		(169,000)
Ending Balance at Mar. 31, 2023	680,318	$ 112,420	5,379	(36,101)	598,620
Ending Balance (in shares) at Mar. 31, 2023		33,127,000
Beginning Balance at Dec. 31, 2022	$ 672,273	$ 122,658	5,447	(46,489)	590,657
Beginning Balance (in shares) at Dec. 31, 2022	33,202,082	33,202,000
Net (loss) income	$ 22,256
Other comprehensive income (loss)	(9,466)
Ending Balance at Sep. 30, 2023	$ 660,052	$ 97,715	5,379	(55,955)	612,913
Ending Balance (in shares) at Sep. 30, 2023	32,795,093	32,795,000
Beginning Balance at Mar. 31, 2023	$ 680,318	$ 112,420	5,379	(36,101)	598,620
Beginning Balance (in shares) at Mar. 31, 2023		33,127,000
Net (loss) income	(1,551)				(1,551)
Other comprehensive income (loss)	(1,312)			(1,312)
Stock compensation, net	3,101	$ 3,101
Stock compensation, net, shares		28,000
Stock repurchase	(9,996)	$ (9,996)
Stock repurchase (in shares)		(167,000)
Ending Balance at Jun. 30, 2023	670,560	$ 105,525	5,379	(37,413)	597,069
Ending Balance (in shares) at Jun. 30, 2023		32,988,000
Net (loss) income	15,844				15,844
Other comprehensive income (loss)	(18,542)			(18,542)
Stock compensation, net	3,291	$ 3,291
Stock compensation, net, shares		2,000
Stock repurchase	(11,101)	$ (11,101)
Stock repurchase (in shares)		(195,000)
Ending Balance at Sep. 30, 2023	$ 660,052	$ 97,715	$ 5,379	$ (55,955)	$ 612,913
Ending Balance (in shares) at Sep. 30, 2023	32,795,093	32,795,000

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Title	directors or Section 16 officers
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Overview

Overview	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Overview	Note 1 – Overview Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive and medical industries. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, valve systems, and other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the U.S., China, Germany and Brazil. The Company is also developing a number of new technologies and products that will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to new product applications for existing and new and adjacent markets. Basis of Presentation and Significant Accounting Policies The unaudited consolidated condensed financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations. The information furnished in the consolidated condensed financial statements include all adjustments (consisting of only normal, recurring adjustments) considered necessary to present fairly the results of operations, financial position and cash flows of the Company. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Principles of Consolidation The consolidated condensed financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in entities in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in entities are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Variable Interest Entities The Company maintains an ownership interest in a VIE, Carrar Ltd. (“Carrar”). Carrar is a technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. The Carrar investment was $ 5,700 and $ 5,200 as of September 30, 2023 and December 31, 2022 , respectively, and is recorded in Other non-current assets in the consolidated condensed balance sheets. Revenue Recognition The Company has no material contract assets or contract liabilities as of September 30, 2023. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year . Total capitalized costs to obtain a contract were $ 4,136 and $ 2,239 as of September 30, 2023 and December 31, 2022 , respectively. These amounts are recorded in Other non-current assets in the consolidated condensed balance sheets and are being amortized into Product revenues in the consolidated condensed statements of income over the expected production life of the applicable program.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2023
Business Combinations [Abstract]
Acquisitions	Note 2 – Acquisitions Alfmeier Präzision SE On August 1, 2022 , the Company acquired 100 % of the equity interests of Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems, integrated electronics and software. The acquisition further expanded the Company's value proposition beyond thermal in comfort, health, wellness, and energy efficiency and aligned with global consumer demand for expanded offerings in vehicle passenger comfort. The total consideration transferred was $ 170,700 . The results of Alfmeier's operations are reported within the Automotive segment from the acquisition date. The acquisition was accounted for as a business combination. The following table summarizes the final purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date: Initial Allocation Measurement Period Adjustments Final Allocation Purchase price, cash consideration, net of cash acquired $ 164,887 $ 5,813 $ 170,700 — Accounts receivable 24,988 ( 121 ) 24,867 Inventory 36,026 417 36,443 Prepaid expenses and other assets 20,920 ( 74 ) 20,846 Operating lease right-of-use assets 4,608 — 4,608 Property and equipment 89,942 1,242 91,184 Other intangible assets 22,668 8,791 31,459 Goodwill 43,678 ( 9,707 ) 33,971 Assumed liabilities ( 55,994 ) 975 ( 55,019 ) Deferred tax liabilities ( 21,949 ) 4,290 ( 17,659 ) Net assets acquired $ 164,887 $ 5,813 $ 170,700 The following table summarizes the final allocation of the purchase consideration to the other intangible assets acquired: Final Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 19,812 14 Technology 11,647 9 Total $ 31,459 Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from combining operations to offer more compelling and high-value solutions across complementary customer relationships as well as expected future synergies. The goodwill is not expected to be deductible for tax purposes. The following unaudited pro forma information represents our product revenues as if the acquisition of Alfmeier had occurred as of January 1, 2022: Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Product revenues $ 352,877 $ 1,004,974 Net income 9,033 21,330 Jiangmen Dacheng Medical Equipment Co. Ltd On July 13, 2022 , the Company acquired 100 % of the equity interests of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. Dacheng is a privately held manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provided Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, and expanded overall manufacturing capacity to include a low-cost manufacturing site. The total consideration transferred was $ 35,048 . The purchase agreement also included potential cash payments contingent upon the achievement of certain performance metrics and continued employment of the former majority shareholder through a series of defined dates. The achievement of these performance metrics resulted in cash payments of $ 500 . These cash payments were accounted for as compensation expense and recorded as a component of Selling, general and administrative expenses ratably over the service period. The acquisition was accounted for as a business combination. The following table summarizes the final purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date: Initial Allocation Measurement Period Adjustments Final Allocation Purchase price, cash consideration, net of cash acquired $ 35,048 $ — $ 35,048 — Accounts receivable 746 ( 124 ) 622 Inventory 1,942 ( 177 ) 1,765 Prepaid expenses and other assets 152 22 174 Operating lease right-of-use assets 841 — 841 Property and equipment 684 — 684 Other intangible assets 19,094 965 20,059 Goodwill 22,995 ( 3,464 ) 19,531 Assumed liabilities ( 2,799 ) ( 515 ) ( 3,314 ) Deferred tax liabilities ( 8,607 ) 3,293 ( 5,314 ) Net assets acquired $ 35,048 $ — $ 35,048 The following table summarizes the final allocation of the purchase consideration to the other intangible assets acquired: Final Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 12,837 12 Technology 4,749 12 Indefinite-lived: Tradenames 2,473 — Total $ 20,059 Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from the enhanced access to high-growth markets including private label opportunities through Dacheng’s innovative patient temperature management devices. The goodwill is not expected to be deductible for tax purposes. The pro forma effects of this acquisition would not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented.

Restructuring and Impairments

Restructuring and Impairments	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Impairments	Note 3 – Restructuring and Impairments The Company continuously monitors market developments, industry trends and changing customer needs and in response, may undertake restructuring actions, as necessary, to execute management’s strategy, streamline operations and optimize the Company’s cost structure. Restructuring actions may include the realignment of existing manufacturing footprint, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in employees receiving voluntary or involuntary employee termination benefits, which are mainly statutory requirements or other contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and when the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. 2023 Manufacturing Footprint Rationalization On September 19, 2023, the Company committed to a restructuring plan (“2023 Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this 2023 Plan, the Company will relocate certain existing manufacturing and related activities in its Greenville, South Carolina facility to a new facility in Monterrey, Mexico. The Company expects to incur total costs of between $ 14,000 and $ 18,000 , of which between $ 13,000 and $ 17,000 are expected to be cash expenditures. The total expected costs include employee severance, retention and termination costs of between $ 2,000 and $ 4,000 , capital expenditures of between $ 7,000 and $ 8,000 and non-cash expenses for accelerated depreciation and impairment of fixed assets of approximately $ 1,000 . The Company also expects to incur other transition costs including recruiting, relocation, and machinery and equipment move and set up costs of between $ 4,000 and $ 5,000 . The actions under this 2023 Plan are expected to be substantially completed by the end of 2025. The actual timing, costs and savings of the 2023 Plan may differ materially from the Company’s current expectations and estimates. During the three and nine months ended September 30, 2023 , the Company did no t recognize any material amounts of restructuring expense. Other Restructuring Activities The Company has undertaken several discrete restructuring actions. During the three and nine months ended September 30, 2023 , the Company recognized $ 1,099 and $ 2,642 , respectively, for employee separation costs and $ 0 and $ 770 , respectively, of other costs. During the three and nine months ended September 30, 2022 , the Company recognized $ 0 and $ 50 , respectively, for employee separation costs and $ 6 and $ 511 , respectively, for other costs. These restructuring expenses were primarily associated with restructuring actions focused on the reduction of global overhead costs. Restructuring Expenses By Reporting Segment The following table summarizes restructuring expense for the three and nine months ended September 30, 2023 and 2022 by reporting segment: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Automotive $ 852 $ 6 $ 2,222 $ 561 Medical — — — — Corporate 247 — 1,190 — Total $ 1,099 $ 6 $ 3,412 $ 561 Restructuring Liability Restructuring liabilities are classified as other current liabilities in the consolidated condensed balance sheets. The following table summarizes restructuring liability for the nine months ended September 30, 2023: Employee Separation Costs Other Related Costs Total Balance at December 31, 2022 $ 588 $ — $ 588 Additions, charged to restructuring expenses 1,206 63 1,269 Cash payments — ( 63 ) ( 63 ) Currency translation 16 — 16 Balance at March 31, 2023 $ 1,810 $ — $ 1,810 Additions, charged to restructuring expenses 337 707 1,044 Cash payments ( 565 ) ( 707 ) ( 1,272 ) Currency translation 6 — 6 Balance at June 30, 2023 $ 1,588 $ — $ 1,588 Additions, charged to restructuring expenses 1,099 — 1,099 Cash payments ( 728 ) — ( 728 ) Currency translation ( 21 ) — ( 21 ) Balance at September 30, 2023 $ 1,938 $ — $ 1,938 Impairments Non-Automotive Electronics Business On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company will continue to sell certain non-automotive electronics products until the exit is complete. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $ 9,378 , $ 5,601 and $ 690 for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment. During the three and nine months ended September 30, 2023 , the Company recorded non-cash impairment charges of $ 3,426 and $ 5,489 , respectively, for the write down of inventory within the Automotive segment. These charges were recorded in Cost of sales. The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers. Medical Segment During the three months ended June 30, 2023, the Company determined that there were impairment indicators for its Medical reporting unit and conducted an impairment analysis, following which the Company concluded that $ 19,509 of goodwill was impaired. Such non-cash impairment charge was recorded in Impairment of goodwill. See Note 5 for additional information about the goodwill impairment analysis.

Details of Certain Balance Shee

Details of Certain Balance Sheet Components	9 Months Ended
	Sep. 30, 2023
Balance Sheet Components [Abstract]
Details of Certain Balance Sheet Components	Note 4 – Details of Certain Balance Sheet Components September 30, 2023 December 31, 2022 Other current assets: Billable tooling $ 13,748 $ 15,267 Income tax and other tax receivable 14,042 15,041 Notes receivable 16,766 12,127 Short-term derivative financial instruments 10,213 6,564 Prepaid expenses 9,503 6,239 Receivables due from factor 6,688 5,490 Other 5,691 3,869 Total other current assets $ 76,651 $ 64,597 Other current liabilities: Accrued employee liabilities $ 39,363 $ 32,031 Liabilities from discounts and rebates 24,790 26,640 Income tax and other taxes payable 11,385 14,459 Accrued warranty 3,206 2,380 Restructuring 1,938 588 Other 9,517 17,716 Total other current liabilities $ 90,199 $ 93,814

Goodwill and Other Intangibles

Goodwill and Other Intangibles	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	Note 5 – Goodwill and Other Intangibles Goodwill Changes in the carrying amount of goodwill, by reportable segment, for the nine months ended September 30, 2023 was as follows: Automotive Medical Total Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774 Impairment of goodwill — ( 19,509 ) ( 19,509 ) Currency translation and other 768 ( 400 ) 368 Balance as of September 30, 2023 $ 73,837 $ 26,796 $ 100,633 Other Intangible Assets Other intangible assets and accumulated amortization balances as of September 30, 2023 and December 31, 2022 were as follows: September 30, 2023 December 31, 2022 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 110,845 $ ( 69,163 ) $ 41,682 $ 112,286 $ ( 65,748 ) $ 46,538 Technology 44,042 ( 27,443 ) 16,599 44,745 ( 25,709 ) 19,036 Product development costs 18,389 ( 18,224 ) 165 18,774 ( 18,456 ) 318 Software development 1,007 — 1,007 1,007 — 1,007 Indefinite-lived: Tradenames 6,974 — 6,974 7,034 — 7,034 Total $ 181,257 $ ( 114,830 ) $ 66,427 $ 183,846 $ ( 109,913 ) $ 73,933 As of December 31, 2022, the estimated fair value of the Medical reporting unit exceeded its carrying value by less than 10 %. During the second quarter of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicated the carrying value of the reporting unit exceeded the fair value of the reporting unit, and accordingly an impairment expense was recorded for $ 19,509 . The Company utilized an income approach to estimate the fair value of the reporting unit and a market valuation approach to further support this analysis (level 3). The income approach was based on projected debt-free cash flow that was discounted to the present value using discount factors that considered the timing and risk of cash flows. Fair value was estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used was the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital includes a company specific risk premium to address the risks associated with achieving the projected revenue and profitability growth rates. Other significant assumptions included terminal value growth rates and terminal value margin rates. Our ability to realize the future cash flows used in our calculations is affected by factors such as the success of strategic initiatives, changes in economic conditions, changes in our operating performance and changes in our business strategies. To further support the fair value estimate determined by the income approach, the Company utilized a market valuation approach to estimate the fair value of the Medical reporting unit. The market approach considered historical and anticipated financial metrics of the Medical reporting unit and applied valuation multiples based on recent observed transactions involving companies similar enough to the Medical reporting unit from which to draw meaningful conclusions.

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	Note 6 – Debt The following table summarizes the Company’s debt as of September 30, 2023 and December 31, 2022: September 30, 2023 December 31, 2022 Interest Principal Interest Principal Credit Agreement: Revolving Credit Facility (U.S. Dollar denominations) 6.79 % $ 207,000 5.80 % $ 232,000 Other loans 3.90 % 247 3.89 % - 5.21 % 2,011 Finance leases 3.54 % 675 3.57 % 1,085 Total debt 207,922 235,096 Current maturities ( 620 ) ( 2,443 ) Long-term debt, less current maturities $ 207,302 $ 232,653 Credit Agreement On June 10, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A., as administrative agent (the “Agent”). The Second Amended and Restated Credit Agreement provides for a $ 500,000 secured revolving credit facility (the “Revolving Credit Facility”), with a $ 50,000 sublimit for swing line loans and a $ 15,000 sublimit for the issuance of standby letters of credit. Any amount of the facility utilized for swing line loans or l etters of credit outstanding will reduce the amount available under the Second Amended and Restated Credit Agreement. The Company had no outstanding l etters of credit issued as of September 30, 2023 and December 31, 2022. Subject to specified conditions, Gentherm can increase the Revolving Credit Facility or incur secured term loans in an aggregate amount of up to $ 200,000 . The Second Amended and Restated Credit Agreement matures on June 10, 2027 . The U.S. borrowers and guarantors participating in the Second Amended and Restated Credit Agreement also entered into a Second Amended and Restated Pledge and Security Agreement (the “Second Amended and Restated Security Agreement”). The Second Amended and Restated Security Agreement grants a security interest to the Agent in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Second Amended and Restated Security Agreement, including the stock and membership interests of specified subsidiaries (limited to 66 % of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Second Amended and Restated Credit Agreement (including all obligations of any U.S. or non-U.S. loan party) are unconditionally guaranteed by certain of Gentherm’s domestic subsidiaries, and the German subsidiary borrowers and certain other foreign subsidiaries guarantee all obligations of the non-U.S. loan parties under the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders. The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. The Second Amended and Restated Credit Agreement also contains customary events of default. As of September 30, 2023, the Company was in compliance with the terms of the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement additionally contains customary events of default. Upon the occurrence of an event of default, the amounts outstanding under the Revolving Credit Facility may be accelerated and may become immediately due and payable. Under the Second Amended and Restated Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Term SOFR rate (“Term SOFR Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate plus 0.50 %, Bank of America’s prime rate, or the Term SOFR rate plus 1.00 %. The rate for Term SOFR Rate Loans denominated in U.S. Dollars is equal to the forward-looking Secured Overnight Financing Rate (“SOFR”) term rate administered by the CME with a term of one month. All loans denominated in a currency other than the U.S. Dollar must be Term SOFR Rate Loans. Interest is payable at least quarterly. Additionally, a commitment fee of between 0.175 % to 0.300 %, which will vary based on the Consolidated Net Leverage Ratio, as defined in the Second Amended and Restated Credit Agreement, is payable on the average daily unused amounts under the Revolving Credit Facility. The Applicable Rate varies based on the Consolidated Net Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Second Amended and Restated Credit Agreement, the lowest and highest possible Applicable Rate is 1.125 % and 2.125 %, respectively, for Term SOFR Rate Loans and 0.125 % and 1.125 %, respectively, for Base Rate Loans. Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and the maximum Consolidated Net Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing four fiscal quarters calculated for purposes of the Consolidated Net Leverag e Ratio, $ 293,000 r emained available as of September 30, 2023 for additional borrowings under the Second Amended and Restated Credit Agreement subject to specified conditions that Gentherm currently satisfies. In connection with the Second Amended and Restated Credit Agreement, the Company incurred debt issuance costs of $ 1,417 , which have been capitalized and are being amortized into Interest expense, net over the term of the credit facility. The scheduled principal maturities of our debt as of September 30, 2023 were as follows: U.S. Other Debt Total 2023 $ — $ 345 $ 345 2024 — 365 365 2025 — 146 146 2026 — 66 66 2027 207,000 — 207,000 2028 — — — Total $ 207,000 $ 922 $ 207,922

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Legal and other contingencies The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters will not have a material adverse effect on its results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves. Product Liability and Warranty Matters In the event that the Company’s products fail to perform as expected or result in alleged bodily injury or property damage, our products may subject us to warranty claims and product liability. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims or liabilities in the future or that it will not incur significant costs to defend such claims. The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including any claims filed by customers, the warranty accrual is adjusted quarterly to reflect management’s estimate of future claims. The following is a reconciliation of the changes in accrued warranty costs: Nine Months Ended September 30, 2023 2022 Balance at the beginning of the period $ 2,380 $ 1,916 Warranty opening balance from acquired entities — 907 Warranty claims paid ( 1,979 ) ( 890 ) Warranty expense for products shipped during the current period 3,311 1,963 Adjustments to warranty estimates from prior periods ( 434 ) ( 200 ) Adjustments due to currency translation ( 72 ) ( 106 ) Balance at the end of the period $ 3,206 $ 3,590 Other matters Purchase commitments for materials, supplies, services and capital expenditures, as part of the normal course of business, are generally consistent from year to year. In addition, due to supply shortages of semiconductors, the Company has entered into agreements with various suppliers to reserve the right to purchase certain semiconductor chips over rolling periods of 12 - 24 months , with volume commitments determined based on our anticipated production requirements. As of September 30, 2023 , the Company’s total commitments for these semiconductor chip agreements was $ 25,603 . Such agreements provide the Company with priority access to semiconductor chips as they become available, however, these agreements do not guarantee that our suppliers will meet the timing and quantities requested by Gentherm. All other purchase commitments as of September 30, 2023 were immaterial.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Note 8 – Earnings Per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents. The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net income $ 15,844 $ 9,827 $ 22,256 $ 28,646 Basic weighted average shares of Common Stock outstanding 32,944,386 33,162,181 33,049,097 33,105,854 Dilutive effect of stock options, restricted stock awards and restricted stock units 251,614 308,258 261,504 353,896 Diluted weighted average shares of Common Stock outstanding 33,196,000 33,470,439 33,310,601 33,459,750 Basic earnings per share $ 0.48 $ 0.30 $ 0.67 $ 0.87 Diluted earnings per share $ 0.48 $ 0.29 $ 0.67 $ 0.86

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Note 9 – Financial Instruments Derivative Financial Instruments The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong. The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of designated foreign currency and copper commodity hedging instruments, if any, to Cost of sales in the consolidated condensed statements of income. Cash flows associated with derivatives are reported in Net cash provided by operating activities in the consolidated condensed statements of cash flows. The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term. The Company is party to a floating-to-fixed interest rate swap agreement with a notional amount of $ 100,000 and a maturity date of July 2025 . This interest rate swap is an undesignated hedge of the Company’s exposure to interest payment fluctuations on a portion of the Revolving Credit Facility borrowings that were drawn for the acquisitions of Alfmeier and Dacheng. The periodic changes in fair value is recognized in Interest expense, net. Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of September 30, 2023 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 103,771 Other current assets $ 6,706 Other current liabilities $ — $ 6,706 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 3,506 Other current liabilities $ — $ 3,506 Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of December 31, 2022 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 40,063 Other current assets $ 3,791 Other current liabilities $ — $ 3,791 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,772 Other current liabilities $ — $ 2,772 Information relating to the effect of derivative instruments on our consolidated condensed statements of income and the consolidated condensed statements of comprehensive income is as follows: Three Months Ended September 30, Nine Months Ended September 30, Location (Income/(Loss)) 2023 2022 2023 2022 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 2,771 $ 321 $ 5,814 $ 807 Other comprehensive income (loss) ( 2,673 ) 1,627 2,915 1,921 Total foreign currency derivatives $ 98 $ 1,948 $ 8,729 $ 2,728 Commodity derivatives Cost of sales – income $ — $ — $ — $ 19 Other comprehensive loss — — — ( 6 ) Total commodity derivatives $ — $ — $ — $ 13 Derivatives Not Designated as Hedging Instruments Foreign currency derivatives Foreign currency gain $ — $ ( 4,288 ) $ — $ ( 3,806 ) Total foreign currency derivatives $ — $ ( 4,288 ) $ — $ ( 3,806 ) Interest rate contracts Interest expense, net $ 62 $ 3,191 $ 734 $ 2,498 Total interest rate derivatives $ 62 $ 3,191 $ 734 $ 2,498 The Company did no t incur any hedge ineffectiveness during the three and nine months ended September 30, 2023 and 2022. Accounts Receivable Factoring The Company sells certain customer trade receivables on a non-recourse basis under factoring arrangements with designated financial institutions. The sale of receivables under these agreements is considered an off-balance sheet arrangement to the Company and is accounted for as a true sale and excluded from accounts receivable in the consolidated condensed balance sheets. These factoring arrangements include a deferred purchase price component in which a portion of the purchase price for the receivable is paid by the financial institution in cash upon sale and the remaining portion is recorded as a deferred purchase price receivable and paid at a later date. Deferred purchase price receivables are recorded in Other current assets within the consolidated condensed balance sheets. Cash proceeds received upon the sale of the receivables are included in Net cash provided by operating activities and the cash proceeds received on the deferred purchase price receivables are included in Net cash used in investing activities. All factoring arrangements incorporate customary representations, including representations as to validity of amounts due, completeness of performance obligations and absence of commercial disputes. Receivables factored and availability under receivables factoring agreements balances as of September 30, 2023 and December 31, 2022 were as follows: September 30, 2023 December 31, 2022 Receivables factored and outstanding $ 22,372 $ 19,108 Amount available under the credit limit 1,169 5,034 Collective factoring limit $ 23,541 $ 24,142 Trade receivables sold and factoring fees incurred during the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 (a) 2023 2022 (a) Trade receivables sold $ 35,115 $ 23,706 $ 111,915 $ 23,706 Factoring fees incurred 221 64 588 64 Represents trade receivables sold and factoring fees incurred since the acquisition of Alfmeier (acquired on August 1, 2022) .

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10 – Fair Value Measurements Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques: Market : This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Income : This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations. Cost : This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost). The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below: Level 1 : Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 : Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability. Level 3 : Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Items Measured at Fair Value on a Recurring Basis Except for derivative instruments (see Note 9) and pension plan assets, the Company had no material financial assets and liabilities that were carried at fair value at September 30, 2023 and December 31, 2022. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value. Items Measured at Fair Value on a Nonrecurring Basis The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. The Company utilized a third-party to assist in the Level 3 fair value estimates of other intangible assets for acquisitions (see Note 2) and goodwill of the Medical reporting unit (see Note 5). The estimated fair values of these assets were based on third-party valuations and management’s estimates, generally utilizing income and market approaches. As of September 30, 2023, and December 31, 2022 , there were no other significant assets or liabilities measured at fair value on a non-recurring basis. Items Not Carried at Fair Value The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of September 30, 2023, and December 31, 2022 , the carrying values of the indebtedness under the Company’s Second Amended and Restated Credit Agreement were not materially different than the estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 6).

Equity

Equity	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Equity	Note 11 – Equity In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”). Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $ 150,000 of its issued and outstanding common stock over a three-year period, expiring December 15, 2023 . Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the three and nine months ended September 30, 2023 , the Company repurchased $ 11,101 and $ 31,094 , respectively, of shares under the 2020 Stock Repurchase Program with an average price paid per share of $ 56.91 and $ 58.54 , respectively. The 2020 Stock Repurchase Program had $ 98,906 of repurchase authorization remaining as of September 30, 2023 .

Reclassifications Out of Accumu

Reclassifications Out of Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Reclassifications Out of Accumulated Other Comprehensive Loss	Note 12 – Reclassifications Out of Accumulated Other Comprehensive Loss Reclassification adjustments and other activities impacting Accumulated other comprehensive loss during the three and nine months ended September 30, 2023 and 2022 were as follows: Defined Foreign Foreign Commodity Hedge Total Balance at June 30, 2023 $ ( 1,059 ) $ ( 43,602 ) $ 7,248 $ — $ ( 37,413 ) Other comprehensive (loss) income before reclassifications — ( 16,321 ) 98 — ( 16,223 ) Income tax effect of other comprehensive (loss) income before reclassifications — ( 135 ) ( 21 ) — ( 156 ) Amounts reclassified from accumulated other comprehensive loss into net income 5 — ( 2,771 ) a — a ( 2,766 ) Income taxes reclassified into net income ( 1 ) — 604 — 603 Net current period other comprehensive income (loss) 4 ( 16,456 ) ( 2,090 ) — ( 18,542 ) Balance at September 30, 2023 $ ( 1,055 ) $ ( 60,058 ) $ 5,158 $ — $ ( 55,955 ) (a) The amounts reclassified from Accumulated other comprehensi ve loss w ere included in Cost of sales. Defined Foreign Foreign Commodity Hedge Total Balance at June 30, 2022 $ ( 2,837 ) $ ( 66,182 ) $ 371 $ — $ ( 68,648 ) Other comprehensive (loss) income before reclassifications — ( 28,411 ) 1,948 — ( 26,463 ) Income tax effect of other comprehensive (loss) income before reclassifications — ( 271 ) ( 423 ) — ( 694 ) Amounts reclassified from accumulated other comprehensive loss into net income 6 — ( 321 ) a — a ( 315 ) Income taxes reclassified into net income — — 69 — 69 Net current period other comprehensive income (loss) 6 ( 28,682 ) 1,273 — ( 27,403 ) Balance at September 30, 2022 $ ( 2,831 ) $ ( 94,864 ) $ 1,644 $ — $ ( 96,051 ) (a) The amounts reclassified from Accumulated other comprehe nsive loss wer e included in Cost of sales. Defined Foreign Foreign Commodity Hedge Total Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ 2,847 $ — $ ( 46,489 ) Other comprehensive (loss) income before reclassifications — ( 11,741 ) 8,729 — ( 3,012 ) Income tax effect of other comprehensive (loss) income before reclassifications — ( 48 ) ( 1,901 ) — ( 1,949 ) Amounts reclassified from accumulated other comprehensive loss into net income 17 — ( 5,814 ) a — a ( 5,797 ) Income taxes reclassified into net income ( 5 ) — 1,297 — 1,292 Net current period other comprehensive income (loss) 12 ( 11,789 ) 2,311 — ( 9,466 ) Balance at September 30, 2023 $ ( 1,055 ) $ ( 60,058 ) $ 5,158 $ — $ ( 55,955 ) (a) The amounts reclassified from Accumulated other comprehe nsive loss wer e included in Cost of sales. Defined Foreign Foreign Commodity Hedge Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 154 $ 5 $ ( 36,922 ) Other comprehensive (loss) income before reclassifications — ( 60,023 ) 2,728 13 ( 57,282 ) Income tax effect of other comprehensive (loss) income before reclassifications — ( 653 ) ( 606 ) ( 3 ) ( 1,262 ) Amounts reclassified from accumulated other comprehensive loss into net income 76 — ( 807 ) a ( 19 ) a ( 750 ) Income taxes reclassified into net income ( 14 ) — 175 4 165 Net current period other comprehensive income (loss) 62 ( 60,676 ) 1,490 ( 5 ) ( 59,129 ) Balance at September 30, 2022 $ ( 2,831 ) $ ( 94,864 ) $ 1,644 $ — $ ( 96,051 ) (a) The amounts reclassified from Accumulated other compreh ensive loss were included in Cost of sales. The Company expects that substantially all of the existing gains and losses related to foreign currency derivatives reported in Accumulated other comprehensive loss as of September 30, 2023 to be reclassified into earnings during the next twelve months. See Note 9 for additional information about derivative financial instruments and the effects from reclassification to Net income.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 13 – Income Taxes At the end of each interim period, the Company makes an estimate of the annual expected effective income tax rate and applies that rate to its ordinary year-to-date earnings or loss. The income tax provision or benefit related to unusual or infrequent items, if applicable, that will be separately reported or reported net of their related tax effects are individually computed and recognized in the interim period in which those items occur. In addition, the effect of changes in enacted tax laws or rates, tax status, judgment on the realizability of a beginning-of-the-year deferred tax asset in future years or income tax contingencies is recognized in the interim period in which the change occurs. The computation of the annual expected effective income tax rate at each interim period requires certain estimates and assumptions including, but not limited to, the expected pre-tax income (or loss) for the year, projections of the proportion of income (and/or loss) earned and taxed in respective jurisdictions, permanent and temporary differences, and the likelihood of the realizability of deferred tax assets generated in the current year. Jurisdictions with a projected loss for the year for which no tax benefit can be recognized due to a valuation allowance are excluded from the estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the composition and timing of actual earnings compared to annual projections. The estimates used to compute the provision or benefit for income taxes may change as new events occur, additional information is obtained or as our tax environment changes. To the extent that the expected annual effective income tax rate changes, the effect of the change on prior interim periods is included in the income tax provision in the period in which the change in estimate occurs. A summary of the provision for income taxes and the corresponding effective tax rate for the three and nine months ended September 30, 2023 and 2022, is shown below: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Income tax expense $ 6,908 $ 5,784 $ 15,478 $ 13,998 Earnings before income tax $ 22,752 $ 15,611 $ 37,734 $ 42,644 Effective tax rate 30.4 % 37.1 % 41.0 % 32.8 % Income tax expense was $ 6,908 for the three months ended September 30, 2023 on earnings before income tax of $ 22,752 , representing an effective tax rate of 30.4 % .The effective tax rate differed from the U.S. Federal statutory rate of 21.0 % primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate and the unfavorable impact of the global intangible low-tax income (“GILTI”), partially offset by the impact of the release of accruals for uncertain tax positions. Income tax expense was $ 5,784 for the three months ended September 30, 2022 on earnings before income tax of $ 15,611 , representing an effective tax rate of 37.1 % . The effective tax rate differed from the U.S. Federal statutory rate of 21.0 % primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the GILTI, and the quarterly accrual for uncertain tax positions partially offset by the impact of certain favorable tax effects of equity vesting. Income tax expense was $ 15,478 for the nine months ended September 30, 2023 on earnings before income tax of $ 37,734 , representing an effective tax rate of 41.0 % . The pre-tax earnings included the effect of an impairment loss of $ 19,509 with a tax benefit of $ 2,255 . The effective tax rate differed from the U.S. Federal statutory rate of 21 % primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate and the unfavorable impact of the GILTI, partially offset by the impact of research and development credits in various jurisdictions, certain favorable tax effects of equity vesting and the release of accruals for uncertain tax positions. Income tax expense was $ 13,998 for the nine months ended September 30, 2022 on earnings before income tax of $ 42,644 , representing an effective tax rate of 32.8 % . The effective tax rate differed from the U.S. Federal statutory rate of 21.0 % primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the GILTI, and the quarterly accrual for uncertain tax positions partially offset by the impact of certain favorable tax effects of equity vesting.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Reporting	Note 14 – Segment Reporting Segment information is used by management for making operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss. The Company’s reportable segments are as follows: • Automotive – this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, lumbar and massage comfort solutions, valve systems, battery performance solutions, and automotive electronic and software systems. • Medical – this segment represents the results from our patient temperature management business within the medical industry. The Corporate category includes unallocated costs related to our corporate headquarter activities, including selling, general and administrative costs and acquisition transaction costs, which do not meet the requirements for being classified as an operating segment. The tables below present segment information about the reported Product revenues, Depreciation and amortization and Operating income (loss) of the Company for the three and nine months ended September 30, 2023 and 2022. Three Months Ended September 30, Automotive Medical Corporate Total 2023 Product revenues $ 354,782 $ 11,413 $ — $ 366,195 Depreciation and amortization 11,399 882 173 $ 12,454 Operating income (loss) 41,690 ( 805 ) ( 17,144 ) $ 23,741 2022 Product revenues $ 322,555 $ 10,407 $ — $ 332,962 Depreciation and amortization 10,499 1,035 302 $ 11,836 Operating income (loss) 43,067 ( 2,232 ) ( 18,014 ) $ 22,821 Nine Months Ended September 30, Automotive Medical Corporate Total 2023 Product revenues $ 1,069,007 $ 33,136 $ — $ 1,102,143 Depreciation and amortization 34,910 2,756 865 $ 38,531 Operating income (loss) 126,630 ( 21,838 ) ( 59,056 ) $ 45,736 2022 Product revenues $ 829,570 $ 31,764 $ — $ 861,334 Depreciation and amortization 27,333 2,224 913 $ 30,470 Operating income (loss) 98,367 ( 3,264 ) ( 50,356 ) $ 44,747 Automotive and Medical segment Product revenues by product category for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Climate Control Seat $ 124,905 $ 112,059 $ 360,868 $ 311,281 Seat Heaters 77,238 75,568 231,132 210,367 Steering Wheel Heaters 39,861 31,482 115,166 89,169 Lumbar and Massage Comfort Solutions (a) 33,260 22,740 109,602 22,740 Valve Systems (a) 27,830 18,542 82,516 18,542 Automotive Cables 19,668 18,338 60,131 59,662 Battery Performance Solutions 17,242 20,331 57,138 55,395 Electronics 10,163 12,083 30,456 33,190 Other Automotive 4,615 11,412 21,998 29,224 Subtotal Automotive segment 354,782 322,555 1,069,007 829,570 Medical segment (b) 11,413 10,407 33,136 31,764 Total Company $ 366,195 $ 332,962 $ 1,102,143 $ 861,334 (a) Represents Product revenues from Alfmeier (acquired on August 1, 2022) - (see Note 2) (b) Includes Product revenues of $ 1,988 and $ 4,939 for the three and nine months ended September 30, 2023 , respectively, and $ 1,234 for the three and nine months ended September 30, 2022 from Dacheng (acquired on July 13, 2022) - (see Note 2) Total Product revenues information by geographic area for the three and nine months ended September 30, 2023 and 2022 is as follows (based on shipment destination): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 United States $ 134,588 $ 131,021 $ 414,359 $ 337,759 China 61,004 57,439 161,530 127,183 South Korea 27,369 22,751 86,102 67,632 Germany 24,456 19,454 77,007 54,805 Czech Republic 16,684 13,247 51,706 35,630 Japan 16,906 17,603 44,995 42,305 Romania 13,828 11,592 39,797 35,866 Slovakia 10,946 8,109 35,254 25,755 Mexico 15,251 7,062 34,701 16,171 Finland 8,286 9,757 29,558 26,244 Other 36,877 34,927 127,134 91,984 Total Non-U.S. 231,607 201,941 687,784 523,575 Total Company $ 366,195 $ 332,962 $ 1,102,143 $ 861,334

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies The unaudited consolidated condensed financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations. The information furnished in the consolidated condensed financial statements include all adjustments (consisting of only normal, recurring adjustments) considered necessary to present fairly the results of operations, financial position and cash flows of the Company. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Principles of Consolidation	Principles of Consolidation The consolidated condensed financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in entities in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in entities are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.
Variable Interest Entities	Variable Interest Entities The Company maintains an ownership interest in a VIE, Carrar Ltd. (“Carrar”). Carrar is a technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. The Carrar investment was $ 5,700 and $ 5,200 as of September 30, 2023 and December 31, 2022 , respectively, and is recorded in Other non-current assets in the consolidated condensed balance sheets.
Revenue Recognition	Revenue Recognition The Company has no material contract assets or contract liabilities as of September 30, 2023. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year . Total capitalized costs to obtain a contract were $ 4,136 and $ 2,239 as of September 30, 2023 and December 31, 2022 , respectively. These amounts are recorded in Other non-current assets in the consolidated condensed balance sheets and are being amortized into Product revenues in the consolidated condensed statements of income over the expected production life of the applicable program.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2023
Alfmeier
Business Acquisition [Line Items]
Summary of Purchase Consideration and Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the final purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date: Initial Allocation Measurement Period Adjustments Final Allocation Purchase price, cash consideration, net of cash acquired $ 164,887 $ 5,813 $ 170,700 — Accounts receivable 24,988 ( 121 ) 24,867 Inventory 36,026 417 36,443 Prepaid expenses and other assets 20,920 ( 74 ) 20,846 Operating lease right-of-use assets 4,608 — 4,608 Property and equipment 89,942 1,242 91,184 Other intangible assets 22,668 8,791 31,459 Goodwill 43,678 ( 9,707 ) 33,971 Assumed liabilities ( 55,994 ) 975 ( 55,019 ) Deferred tax liabilities ( 21,949 ) 4,290 ( 17,659 ) Net assets acquired $ 164,887 $ 5,813 $ 170,700
Summary of Final Allocation of Purchase Consideration to Other Intangible Assets Acquired	The following table summarizes the final allocation of the purchase consideration to the other intangible assets acquired: Final Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 19,812 14 Technology 11,647 9 Total $ 31,459
Summary of Unaudited Pro Forma Information	The following unaudited pro forma information represents our product revenues as if the acquisition of Alfmeier had occurred as of January 1, 2022: Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Product revenues $ 352,877 $ 1,004,974 Net income 9,033 21,330
Dacheng
Business Acquisition [Line Items]
Summary of Purchase Consideration and Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the final purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date: Initial Allocation Measurement Period Adjustments Final Allocation Purchase price, cash consideration, net of cash acquired $ 35,048 $ — $ 35,048 — Accounts receivable 746 ( 124 ) 622 Inventory 1,942 ( 177 ) 1,765 Prepaid expenses and other assets 152 22 174 Operating lease right-of-use assets 841 — 841 Property and equipment 684 — 684 Other intangible assets 19,094 965 20,059 Goodwill 22,995 ( 3,464 ) 19,531 Assumed liabilities ( 2,799 ) ( 515 ) ( 3,314 ) Deferred tax liabilities ( 8,607 ) 3,293 ( 5,314 ) Net assets acquired $ 35,048 $ — $ 35,048
Summary of Final Allocation of Purchase Consideration to Other Intangible Assets Acquired	The following table summarizes the final allocation of the purchase consideration to the other intangible assets acquired: Final Fair Value Weighted Average Life (in years) Definite-lived: Customer related $ 12,837 12 Technology 4,749 12 Indefinite-lived: Tradenames 2,473 — Total $ 20,059

Restructuring and Impairments (

Restructuring and Impairments (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Summary of Restructuring Expense by Reportable Segment	The following table summarizes restructuring expense for the three and nine months ended September 30, 2023 and 2022 by reporting segment: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Automotive $ 852 $ 6 $ 2,222 $ 561 Medical — — — — Corporate 247 — 1,190 — Total $ 1,099 $ 6 $ 3,412 $ 561
Summary of Restructuring Liability	Restructuring liabilities are classified as other current liabilities in the consolidated condensed balance sheets. The following table summarizes restructuring liability for the nine months ended September 30, 2023: Employee Separation Costs Other Related Costs Total Balance at December 31, 2022 $ 588 $ — $ 588 Additions, charged to restructuring expenses 1,206 63 1,269 Cash payments — ( 63 ) ( 63 ) Currency translation 16 — 16 Balance at March 31, 2023 $ 1,810 $ — $ 1,810 Additions, charged to restructuring expenses 337 707 1,044 Cash payments ( 565 ) ( 707 ) ( 1,272 ) Currency translation 6 — 6 Balance at June 30, 2023 $ 1,588 $ — $ 1,588 Additions, charged to restructuring expenses 1,099 — 1,099 Cash payments ( 728 ) — ( 728 ) Currency translation ( 21 ) — ( 21 ) Balance at September 30, 2023 $ 1,938 $ — $ 1,938

Details of Certain Balance Sh_2

Details of Certain Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2023
Balance Sheet Components [Abstract]
Summary of Certain Balance Sheet Components	September 30, 2023 December 31, 2022 Other current assets: Billable tooling $ 13,748 $ 15,267 Income tax and other tax receivable 14,042 15,041 Notes receivable 16,766 12,127 Short-term derivative financial instruments 10,213 6,564 Prepaid expenses 9,503 6,239 Receivables due from factor 6,688 5,490 Other 5,691 3,869 Total other current assets $ 76,651 $ 64,597 Other current liabilities: Accrued employee liabilities $ 39,363 $ 32,031 Liabilities from discounts and rebates 24,790 26,640 Income tax and other taxes payable 11,385 14,459 Accrued warranty 3,206 2,380 Restructuring 1,938 588 Other 9,517 17,716 Total other current liabilities $ 90,199 $ 93,814

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment	Changes in the carrying amount of goodwill, by reportable segment, for the nine months ended September 30, 2023 was as follows: Automotive Medical Total Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774 Impairment of goodwill — ( 19,509 ) ( 19,509 ) Currency translation and other 768 ( 400 ) 368 Balance as of September 30, 2023 $ 73,837 $ 26,796 $ 100,633
Summary of Other Intangible Assets and Accumulated Amortization Balances	Other intangible assets and accumulated amortization balances as of September 30, 2023 and December 31, 2022 were as follows: September 30, 2023 December 31, 2022 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Definite-lived: Customer relationships $ 110,845 $ ( 69,163 ) $ 41,682 $ 112,286 $ ( 65,748 ) $ 46,538 Technology 44,042 ( 27,443 ) 16,599 44,745 ( 25,709 ) 19,036 Product development costs 18,389 ( 18,224 ) 165 18,774 ( 18,456 ) 318 Software development 1,007 — 1,007 1,007 — 1,007 Indefinite-lived: Tradenames 6,974 — 6,974 7,034 — 7,034 Total $ 181,257 $ ( 114,830 ) $ 66,427 $ 183,846 $ ( 109,913 ) $ 73,933

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Summary of Company's Debt	The following table summarizes the Company’s debt as of September 30, 2023 and December 31, 2022: September 30, 2023 December 31, 2022 Interest Principal Interest Principal Credit Agreement: Revolving Credit Facility (U.S. Dollar denominations) 6.79 % $ 207,000 5.80 % $ 232,000 Other loans 3.90 % 247 3.89 % - 5.21 % 2,011 Finance leases 3.54 % 675 3.57 % 1,085 Total debt 207,922 235,096 Current maturities ( 620 ) ( 2,443 ) Long-term debt, less current maturities $ 207,302 $ 232,653
Principal Maturities of Debt	The scheduled principal maturities of our debt as of September 30, 2023 were as follows: U.S. Other Debt Total 2023 $ — $ 345 $ 345 2024 — 365 365 2025 — 146 146 2026 — 66 66 2027 207,000 — 207,000 2028 — — — Total $ 207,000 $ 922 $ 207,922

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Reconciliation of Changes in Accrued Warranty Costs	The following is a reconciliation of the changes in accrued warranty costs: Nine Months Ended September 30, 2023 2022 Balance at the beginning of the period $ 2,380 $ 1,916 Warranty opening balance from acquired entities — 907 Warranty claims paid ( 1,979 ) ( 890 ) Warranty expense for products shipped during the current period 3,311 1,963 Adjustments to warranty estimates from prior periods ( 434 ) ( 200 ) Adjustments due to currency translation ( 72 ) ( 106 ) Balance at the end of the period $ 3,206 $ 3,590

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings per Share and Weighted Average Shares Outstanding Used in Calculating Basic and Diluted Earnings per Share	The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Net income $ 15,844 $ 9,827 $ 22,256 $ 28,646 Basic weighted average shares of Common Stock outstanding 32,944,386 33,162,181 33,049,097 33,105,854 Dilutive effect of stock options, restricted stock awards and restricted stock units 251,614 308,258 261,504 353,896 Diluted weighted average shares of Common Stock outstanding 33,196,000 33,470,439 33,310,601 33,459,750 Basic earnings per share $ 0.48 $ 0.30 $ 0.67 $ 0.87 Diluted earnings per share $ 0.48 $ 0.29 $ 0.67 $ 0.86

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Information Related to Recurring Fair Value Measurement of Derivative Instruments in Our Consolidated Condensed Balance Sheet	Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of September 30, 2023 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 103,771 Other current assets $ 6,706 Other current liabilities $ — $ 6,706 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 3,506 Other current liabilities $ — $ 3,506 Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of December 31, 2022 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 40,063 Other current assets $ 3,791 Other current liabilities $ — $ 3,791 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,772 Other current liabilities $ — $ 2,772
Information Related to Effect of Derivative Instruments on Our Consolidated Condensed Statements of Income and Consolidated Condensed Statements of Comprehensive Income (Loss)	Information relating to the effect of derivative instruments on our consolidated condensed statements of income and the consolidated condensed statements of comprehensive income is as follows: Three Months Ended September 30, Nine Months Ended September 30, Location (Income/(Loss)) 2023 2022 2023 2022 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 2,771 $ 321 $ 5,814 $ 807 Other comprehensive income (loss) ( 2,673 ) 1,627 2,915 1,921 Total foreign currency derivatives $ 98 $ 1,948 $ 8,729 $ 2,728 Commodity derivatives Cost of sales – income $ — $ — $ — $ 19 Other comprehensive loss — — — ( 6 ) Total commodity derivatives $ — $ — $ — $ 13 Derivatives Not Designated as Hedging Instruments Foreign currency derivatives Foreign currency gain $ — $ ( 4,288 ) $ — $ ( 3,806 ) Total foreign currency derivatives $ — $ ( 4,288 ) $ — $ ( 3,806 ) Interest rate contracts Interest expense, net $ 62 $ 3,191 $ 734 $ 2,498 Total interest rate derivatives $ 62 $ 3,191 $ 734 $ 2,498
Summary of Receivables Factored and Availability Under Receivables Factoring Agreements	Receivables factored and availability under receivables factoring agreements balances as of September 30, 2023 and December 31, 2022 were as follows: September 30, 2023 December 31, 2022 Receivables factored and outstanding $ 22,372 $ 19,108 Amount available under the credit limit 1,169 5,034 Collective factoring limit $ 23,541 $ 24,142
Summary of Trade Receivables Sold and Factoring Fees Incurred	Trade receivables sold and factoring fees incurred during the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 (a) 2023 2022 (a) Trade receivables sold $ 35,115 $ 23,706 $ 111,915 $ 23,706 Factoring fees incurred 221 64 588 64 Represents trade receivables sold and factoring fees incurred since the acquisition of Alfmeier (acquired on August 1, 2022)

Reclassifications Out of Accu_2

Reclassifications Out of Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Loss	Reclassification adjustments and other activities impacting Accumulated other comprehensive loss during the three and nine months ended September 30, 2023 and 2022 were as follows: Defined Foreign Foreign Commodity Hedge Total Balance at June 30, 2023 $ ( 1,059 ) $ ( 43,602 ) $ 7,248 $ — $ ( 37,413 ) Other comprehensive (loss) income before reclassifications — ( 16,321 ) 98 — ( 16,223 ) Income tax effect of other comprehensive (loss) income before reclassifications — ( 135 ) ( 21 ) — ( 156 ) Amounts reclassified from accumulated other comprehensive loss into net income 5 — ( 2,771 ) a — a ( 2,766 ) Income taxes reclassified into net income ( 1 ) — 604 — 603 Net current period other comprehensive income (loss) 4 ( 16,456 ) ( 2,090 ) — ( 18,542 ) Balance at September 30, 2023 $ ( 1,055 ) $ ( 60,058 ) $ 5,158 $ — $ ( 55,955 ) (a) The amounts reclassified from Accumulated other comprehensi ve loss w ere included in Cost of sales. Defined Foreign Foreign Commodity Hedge Total Balance at June 30, 2022 $ ( 2,837 ) $ ( 66,182 ) $ 371 $ — $ ( 68,648 ) Other comprehensive (loss) income before reclassifications — ( 28,411 ) 1,948 — ( 26,463 ) Income tax effect of other comprehensive (loss) income before reclassifications — ( 271 ) ( 423 ) — ( 694 ) Amounts reclassified from accumulated other comprehensive loss into net income 6 — ( 321 ) a — a ( 315 ) Income taxes reclassified into net income — — 69 — 69 Net current period other comprehensive income (loss) 6 ( 28,682 ) 1,273 — ( 27,403 ) Balance at September 30, 2022 $ ( 2,831 ) $ ( 94,864 ) $ 1,644 $ — $ ( 96,051 ) (a) The amounts reclassified from Accumulated other comprehe nsive loss wer e included in Cost of sales. Defined Foreign Foreign Commodity Hedge Total Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ 2,847 $ — $ ( 46,489 ) Other comprehensive (loss) income before reclassifications — ( 11,741 ) 8,729 — ( 3,012 ) Income tax effect of other comprehensive (loss) income before reclassifications — ( 48 ) ( 1,901 ) — ( 1,949 ) Amounts reclassified from accumulated other comprehensive loss into net income 17 — ( 5,814 ) a — a ( 5,797 ) Income taxes reclassified into net income ( 5 ) — 1,297 — 1,292 Net current period other comprehensive income (loss) 12 ( 11,789 ) 2,311 — ( 9,466 ) Balance at September 30, 2023 $ ( 1,055 ) $ ( 60,058 ) $ 5,158 $ — $ ( 55,955 ) (a) The amounts reclassified from Accumulated other comprehe nsive loss wer e included in Cost of sales. Defined Foreign Foreign Commodity Hedge Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 154 $ 5 $ ( 36,922 ) Other comprehensive (loss) income before reclassifications — ( 60,023 ) 2,728 13 ( 57,282 ) Income tax effect of other comprehensive (loss) income before reclassifications — ( 653 ) ( 606 ) ( 3 ) ( 1,262 ) Amounts reclassified from accumulated other comprehensive loss into net income 76 — ( 807 ) a ( 19 ) a ( 750 ) Income taxes reclassified into net income ( 14 ) — 175 4 165 Net current period other comprehensive income (loss) 62 ( 60,676 ) 1,490 ( 5 ) ( 59,129 ) Balance at September 30, 2022 $ ( 2,831 ) $ ( 94,864 ) $ 1,644 $ — $ ( 96,051 ) (a) The amounts reclassified from Accumulated other compreh ensive loss were included in Cost of sales.

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Summary of Provision for Income Taxes and Corresponding Effective Tax Rate	A summary of the provision for income taxes and the corresponding effective tax rate for the three and nine months ended September 30, 2023 and 2022, is shown below: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Income tax expense $ 6,908 $ 5,784 $ 15,478 $ 13,998 Earnings before income tax $ 22,752 $ 15,611 $ 37,734 $ 42,644 Effective tax rate 30.4 % 37.1 % 41.0 % 32.8 %

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss)	The tables below present segment information about the reported Product revenues, Depreciation and amortization and Operating income (loss) of the Company for the three and nine months ended September 30, 2023 and 2022. Three Months Ended September 30, Automotive Medical Corporate Total 2023 Product revenues $ 354,782 $ 11,413 $ — $ 366,195 Depreciation and amortization 11,399 882 173 $ 12,454 Operating income (loss) 41,690 ( 805 ) ( 17,144 ) $ 23,741 2022 Product revenues $ 322,555 $ 10,407 $ — $ 332,962 Depreciation and amortization 10,499 1,035 302 $ 11,836 Operating income (loss) 43,067 ( 2,232 ) ( 18,014 ) $ 22,821 Nine Months Ended September 30, Automotive Medical Corporate Total 2023 Product revenues $ 1,069,007 $ 33,136 $ — $ 1,102,143 Depreciation and amortization 34,910 2,756 865 $ 38,531 Operating income (loss) 126,630 ( 21,838 ) ( 59,056 ) $ 45,736 2022 Product revenues $ 829,570 $ 31,764 $ — $ 861,334 Depreciation and amortization 27,333 2,224 913 $ 30,470 Operating income (loss) 98,367 ( 3,264 ) ( 50,356 ) $ 44,747
Segment Information About Reported Segment Product Revenues by Product Category	Automotive and Medical segment Product revenues by product category for the three and nine months ended September 30, 2023 and 2022 were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Climate Control Seat $ 124,905 $ 112,059 $ 360,868 $ 311,281 Seat Heaters 77,238 75,568 231,132 210,367 Steering Wheel Heaters 39,861 31,482 115,166 89,169 Lumbar and Massage Comfort Solutions (a) 33,260 22,740 109,602 22,740 Valve Systems (a) 27,830 18,542 82,516 18,542 Automotive Cables 19,668 18,338 60,131 59,662 Battery Performance Solutions 17,242 20,331 57,138 55,395 Electronics 10,163 12,083 30,456 33,190 Other Automotive 4,615 11,412 21,998 29,224 Subtotal Automotive segment 354,782 322,555 1,069,007 829,570 Medical segment (b) 11,413 10,407 33,136 31,764 Total Company $ 366,195 $ 332,962 $ 1,102,143 $ 861,334 (a) Represents Product revenues from Alfmeier (acquired on August 1, 2022) - (see Note 2) (b) Includes Product revenues of $ 1,988 and $ 4,939 for the three and nine months ended September 30, 2023 , respectively, and $ 1,234 for the three and nine months ended September 30, 2022 from Dacheng (acquired on July 13, 2022) - (see Note 2)
Product Revenues Information by Geographic Area	Total Product revenues information by geographic area for the three and nine months ended September 30, 2023 and 2022 is as follows (based on shipment destination): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 United States $ 134,588 $ 131,021 $ 414,359 $ 337,759 China 61,004 57,439 161,530 127,183 South Korea 27,369 22,751 86,102 67,632 Germany 24,456 19,454 77,007 54,805 Czech Republic 16,684 13,247 51,706 35,630 Japan 16,906 17,603 44,995 42,305 Romania 13,828 11,592 39,797 35,866 Slovakia 10,946 8,109 35,254 25,755 Mexico 15,251 7,062 34,701 16,171 Finland 8,286 9,757 29,558 26,244 Other 36,877 34,927 127,134 91,984 Total Non-U.S. 231,607 201,941 687,784 523,575 Total Company $ 366,195 $ 332,962 $ 1,102,143 $ 861,334

Overview - Additional Informati

Overview - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Investment amount	$ 5,700	$ 5,200
Capitalized costs to obtain contract	$ 4,136	$ 2,239
Entities Ownership Interest
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Ownership interest	20%
Minimum
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Expected period of costs to be realized to recognize assets	1 year

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 01, 2022	Jul. 13, 2022	Sep. 30, 2023
Alfmeier
Business Acquisition [Line Items]
Acquisition date	Aug. 01, 2022
Percentage of equity interests acquired	100%
Total consideration	$ 170,700
Net assets acquired			$ 170,700
Alfmeier | Measurement Period Adjustments
Business Acquisition [Line Items]
Net assets acquired	$ 5,813
Dacheng
Business Acquisition [Line Items]
Acquisition date		Jul. 13, 2022
Percentage of equity interests acquired		100%
Total consideration		$ 35,048
Contingent payments		$ 500
Net assets acquired			$ 35,048

Acquisitions - Summary of Purch

Acquisitions - Summary of Purchase Consideration and Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands			9 Months Ended
	Aug. 01, 2022	Jul. 13, 2022	Sep. 30, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill			$ 100,633	$ 119,774
Alfmeier
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired			170,700
Accounts receivable			24,867
Inventory			36,443
Prepaid expenses and other assets			20,846
Operating lease right-of-use assets			4,608
Property and equipment			91,184
Other intangible assets	$ 31,459		31,459
Goodwill			33,971
Assumed liabilities			(55,019)
Deferred tax liabilities			(17,659)
Net assets acquired			170,700
Alfmeier | Initial Allocation
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired	164,887
Accounts receivable	24,988
Inventory	36,026
Prepaid expenses and other assets	20,920
Operating lease right-of-use assets	4,608
Property and equipment	89,942
Other intangible assets	22,668
Goodwill	43,678
Assumed liabilities	(55,994)
Deferred tax liabilities	(21,949)
Net assets acquired	164,887
Alfmeier | Measurement Period Adjustments
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired	5,813
Accounts receivable	(121)
Inventory	417
Prepaid expenses and other assets	(74)
Property and equipment	1,242
Other intangible assets	8,791
Goodwill	(9,707)
Assumed liabilities	975
Deferred tax liabilities	4,290
Net assets acquired	$ 5,813
Dacheng
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired			35,048
Accounts receivable			622
Inventory			1,765
Prepaid expenses and other assets			174
Operating lease right-of-use assets			841
Property and equipment			684
Other intangible assets		$ 20,059	20,059
Goodwill			19,531
Assumed liabilities			(3,314)
Deferred tax liabilities			(5,314)
Net assets acquired			$ 35,048
Dacheng | Initial Allocation
Business Acquisition [Line Items]
Purchase price, cash consideration, net of cash acquired		35,048
Accounts receivable		746
Inventory		1,942
Prepaid expenses and other assets		152
Operating lease right-of-use assets		841
Property and equipment		684
Other intangible assets		19,094
Goodwill		22,995
Assumed liabilities		(2,799)
Deferred tax liabilities		(8,607)
Net assets acquired		35,048
Dacheng | Measurement Period Adjustments
Business Acquisition [Line Items]
Accounts receivable		(124)
Inventory		(177)
Prepaid expenses and other assets		22
Other intangible assets		965
Goodwill		(3,464)
Assumed liabilities		(515)
Deferred tax liabilities		$ 3,293

Acquisitions - Summary of Final

Acquisitions - Summary of Final Allocation of Purchase Consideration to Other Intangible Assets Acquired (Detail) - USD ($) $ in Thousands	Aug. 01, 2022	Jul. 13, 2022	Sep. 30, 2023
Alfmeier
Business Acquisition [Line Items]
Final Fair Value, Total	$ 31,459		$ 31,459
Alfmeier | Customer Related
Business Acquisition [Line Items]
Final Fair Value, Definite-lived	$ 19,812
Weighted Average Life (in years)	14 years
Alfmeier | Technology
Business Acquisition [Line Items]
Final Fair Value, Definite-lived	$ 11,647
Weighted Average Life (in years)	9 years
Dacheng
Business Acquisition [Line Items]
Final Fair Value, Total		$ 20,059	$ 20,059
Dacheng | Tradenames
Business Acquisition [Line Items]
Final Fair Value, Indefinite-lived		2,473
Dacheng | Customer Related
Business Acquisition [Line Items]
Final Fair Value, Definite-lived		$ 12,837
Weighted Average Life (in years)		12 years
Dacheng | Technology
Business Acquisition [Line Items]
Final Fair Value, Definite-lived		$ 4,749
Weighted Average Life (in years)		12 years

Acquisitions - Summary of Unaud

Acquisitions - Summary of Unaudited Pro Forma Information (Detail) - Alfmeier - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Business Acquisition [Line Items]
Product revenues	$ 352,877	$ 1,004,974
Net income	$ 9,033	$ 21,330

Restructuring and Impairments -

Restructuring and Impairments - Additional Information (Detail) - USD ($)		3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 19, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Restructuring Cost And Reserve [Line Items]
Restructuring expenses		$ 1,099,000			$ 6,000	$ 3,412,000	$ 561,000
Cash payments for restructuring expenses		728,000	$ 1,272,000	$ 63,000
Description and timing of disposal						The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers.
Impairment of goodwill						$ 19,509,000
Medical Segments
Restructuring Cost And Reserve [Line Items]
Impairment of goodwill			19,509,000
Property and Equipment
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges								$ 690,000
Intangible Assets
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges								5,601,000
Inventory
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges		3,426,000				5,489,000		$ 9,378,000
2023 Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses		0				0
Non cash expenses for accelerated depreciation and impairment of fixed assets	$ 1,000,000
2023 Manufacturing Footprint Rationalization | Maximum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	18,000,000
Cash payments for restructuring expenses	17,000,000
Restructuring charges for capital expenditures	8,000,000
2023 Manufacturing Footprint Rationalization | Minimum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	14,000,000
Cash payments for restructuring expenses	13,000,000
Restructuring charges for capital expenditures	7,000,000
Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Other restructuring costs		0			6,000	770,000	511,000
Employee Separation Costs
Restructuring Cost And Reserve [Line Items]
Cash payments for restructuring expenses		728,000	565,000
Employee Separation Costs | Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Restructuring expenses		$ 1,099,000			$ 0	$ 2,642,000	$ 50,000
Employee Severance Retention and Termination Costs | 2023 Manufacturing Footprint Rationalization | Maximum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	4,000,000
Employee Severance Retention and Termination Costs | 2023 Manufacturing Footprint Rationalization | Minimum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	2,000,000
Other Related Costs
Restructuring Cost And Reserve [Line Items]
Cash payments for restructuring expenses			$ 707,000	$ 63,000
Other Related Costs | 2023 Manufacturing Footprint Rationalization | Maximum
Restructuring Cost And Reserve [Line Items]
Future restructuring expenses expected	5,000,000
Other Related Costs | 2023 Manufacturing Footprint Rationalization | Minimum
Restructuring Cost And Reserve [Line Items]
Future restructuring expenses expected	$ 4,000,000

Restructuring and Impairments_2

Restructuring and Impairments - Summary of Restructuring Expense by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 1,099	$ 6	$ 3,412	$ 561
Operating Segments | Automotive Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	852	$ 6	2,222	$ 561
Operating Segments | Corporate Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 247		$ 1,190

Restructuring and Impairments_3

Restructuring and Impairments - Summary of Restructuring Liability (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	$ 1,588	$ 1,810	$ 588
Additions, charged to restructuring expenses	1,099	1,044	1,269
Cash payments	(728)	(1,272)	(63)
Currency translation	(21)	6	16
Balance, end of period	1,938	1,588	1,810
Employee Separation Costs
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period	1,588	1,810	588
Additions, charged to restructuring expenses	1,099	337	1,206
Cash payments	(728)	(565)
Currency translation	(21)	6	16
Balance, end of period	$ 1,938	1,588	1,810
Other Related Costs
Restructuring Cost And Reserve [Line Items]
Additions, charged to restructuring expenses		707	63
Cash payments		$ (707)	$ (63)

Details of Certain Balance Sh_3

Details of Certain Balance Sheet Components (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Billable tooling	$ 13,748	$ 15,267
Income tax and other tax receivable	14,042	15,041
Short-term derivative financial instruments	10,213	6,564
Prepaid expenses	9,503	6,239
Other	5,691	3,869
Total other current assets	76,651	64,597
Other current liabilities:
Accrued employee liabilities	39,363	32,031
Liabilities from discounts and rebates	24,790	26,640
Income tax and other taxes payable	11,385	14,459
Accrued warranty	3,206	2,380	$ 3,590	$ 1,916
Restructuring	1,938	588
Other	9,517	17,716
Total other current liabilities	90,199	93,814
Related Party
Current Assets:
Notes receivable	16,766	12,127
Receivables due from factor	$ 6,688	$ 5,490

Goodwill and Other Intangible_2

Goodwill and Other Intangibles - Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Line Items]
Balance, beginning of period	$ 119,774
Impairment of goodwill	(19,509)
Balance, end of period	100,633
Operating Segments
Goodwill [Line Items]
Balance, beginning of period	119,774
Impairment of goodwill	(19,509)
Currency translation and other	368
Balance, end of period	100,633
Automotive Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	73,069
Currency translation and other	768
Balance, end of period	73,837
Medical Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	46,705
Impairment of goodwill	(19,509)
Currency translation and other	(400)
Balance, end of period	$ 26,796

Goodwill and Other Intangible_3

Goodwill and Other Intangibles - Summary of Other Intangible Assets and Accumulated Amortization Balances (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Intangible Assets [Line Items]
Gross Carrying Value	$ 181,257	$ 183,846
Accumulated Amortization	(114,830)	(109,913)
Net Carrying Value	66,427	73,933
Net Carrying Value	66,427	73,933
Customer Relationships
Intangible Assets [Line Items]
Gross Carrying Value	110,845	112,286
Accumulated Amortization	(69,163)	(65,748)
Net Carrying Value	41,682	46,538
Technology
Intangible Assets [Line Items]
Gross Carrying Value	44,042	44,745
Accumulated Amortization	(27,443)	(25,709)
Net Carrying Value	16,599	19,036
Product development costs
Intangible Assets [Line Items]
Gross Carrying Value	18,389	18,774
Accumulated Amortization	(18,224)	(18,456)
Net Carrying Value	165	318
Software Development
Intangible Assets [Line Items]
Gross Carrying Value	1,007	1,007
Net Carrying Value	1,007	1,007
Tradenames
Intangible Assets [Line Items]
Gross Carrying Value	6,974	7,034
Net Carrying Value	$ 6,974	$ 7,034

Goodwill and Other Intangible_4

Goodwill and Other Intangibles - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Goodwill [Line Items]
Goodwill impairment	$ 19,509
Carrying value percentage		10%
Operating Segments
Goodwill [Line Items]
Goodwill impairment	19,509
Medical Segments | Operating Segments
Goodwill [Line Items]
Goodwill impairment	$ 19,509

Summary of Company's Debt (Deta

Summary of Company's Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total debt	$ 207,922	$ 235,096
Current maturities	(620)	(2,443)
Long-term debt, less current maturities	$ 207,302	$ 232,653
Revolving Credit Facility (U.S. Dollar denominations)
Debt Instrument [Line Items]
Interest Rate	6.79%	5.80%
Total debt	$ 207,000	$ 232,000
Other Loans
Debt Instrument [Line Items]
Interest Rate	3.90%
Total debt	$ 247	$ 2,011
Other Loans | Minimum
Debt Instrument [Line Items]
Interest Rate		3.89%
Other Loans | Maximum
Debt Instrument [Line Items]
Interest Rate		5.21%
Finance Leases
Debt Instrument [Line Items]
Interest Rate	3.54%	3.57%
Total debt	$ 675	$ 1,085

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)		9 Months Ended
	Jun. 10, 2022	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Maximum percentage of stock of non US subsidiaries pledge to secure obligation		66%
Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Debt issuance cost	$ 1,417,000
Remaining borrowing capacity		$ 293,000,000
Second Amended and Restated Credit Agreement | Federal Funds Rate
Debt Instrument [Line Items]
Interest rate		0.50%
Second Amended and Restated Credit Agreement | SOFR Rate
Debt Instrument [Line Items]
Interest rate		1%
Base Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate		0.125%
Base Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate		1.125%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate		1.125%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate		2.125%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity increase subject to specified conditions	200,000,000
Revolving Credit Facility | Letters of Credit
Debt Instrument [Line Items]
Line of credit, outstanding amount		$ 0	$ 0
Revolving Credit Facility | Swing Line Loans
Debt Instrument [Line Items]
Maximum borrowing capacity	50,000,000
Revolving Credit Facility | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000
Debt maturity date	Jun. 10, 2027
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Commitment fee percentage payable on average daily unused amounts		0.175%
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Commitment fee percentage payable on average daily unused amounts		0.30%
Standby Letters of Credit | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 15,000,000

Principal Maturities of Debt (D

Principal Maturities of Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Debt maturing in 2023	$ 345
Debt maturing in 2024	365
Debt maturing in 2025	146
Debt maturing in 2026	66
Debt maturing in 2027	207,000
Total debt	207,922	$ 235,096
US and Euro Denominated Revolving Note
Debt Instrument [Line Items]
Debt maturing in 2027	207,000
Total debt	207,000
Other Debt
Debt Instrument [Line Items]
Debt maturing in 2023	345
Debt maturing in 2024	365
Debt maturing in 2025	146
Debt maturing in 2026	66
Total debt	$ 922

Commitments and Contingencies -

Commitments and Contingencies - Reconciliation of Changes in Accrued Warranty Costs (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Loss Contingency [Abstract]
Balance at the beginning of the period	$ 2,380	$ 1,916
Warranty opening balance from acquired entities		907
Warranty claims paid	(1,979)	(890)
Warranty expense for products shipped during the current period	3,311	1,963
Adjustments to warranty estimates from prior periods	(434)	(200)
Adjustments due to currency translation	(72)	(106)
Balance at the end of the period	$ 3,206	$ 3,590

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Detail) - Semiconductor Chips $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Loss Contingencies [Line Items]
Commitments	$ 25,603
Minimum
Loss Contingencies [Line Items]
Commitment period	12 months
Maximum
Loss Contingencies [Line Items]
Commitment period	24 months

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Net income	$ 15,844	$ (1,551)	$ 7,963	$ 9,827	$ 7,072	$ 11,747	$ 22,256	$ 28,646
Basic weighted average shares of Common Stock outstanding	32,944,386			33,162,181			33,049,097	33,105,854
Dilutive effect of stock options, restricted stock awards and restricted stock units	251,614			308,258			261,504	353,896
Diluted weighted average shares of Common Stock outstanding	33,196,000			33,470,439			33,310,601	33,459,750
Basic earnings per share	$ 0.48			$ 0.30			$ 0.67	$ 0.87
Diluted earnings per share	$ 0.48			$ 0.29			$ 0.67	$ 0.86

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Interest Rate Swap
Derivative [Line Items]
Hedge Ineffectiveness Incurred	$ 0	$ 0	$ 0	$ 0
Floating to Fixed interest Rate Swap
Derivative [Line Items]
Notional Value	$ 100,000,000		$ 100,000,000
Maturity date			Jul. 31, 2025

Information Related to Recurrin

Information Related to Recurring Fair Value Measurement of Derivative Instruments in Our Consolidated Condensed Balance Sheet (Detail) - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Foreign Currency Derivatives | Derivatives Designated as Cash Flow Hedges
Derivatives Fair Value [Line Items]
Notional Amount	$ 103,771	$ 40,063
Net Asset/ (Liabilities)	6,706	3,791
Foreign Currency Derivatives | Other Current Assets | Derivatives Designated as Cash Flow Hedges
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	6,706	3,791
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments
Derivatives Fair Value [Line Items]
Notional Amount	100,000	100,000
Net Asset/ (Liabilities)	3,506	2,772
Interest Rate Contracts | Other Current Assets | Derivatives Not Designated as Hedging Instruments
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 3,506	$ 2,772

Information Related to Effect o

Information Related to Effect of Derivative Instruments on Our Consolidated Condensed Statements of Income and Consolidated Condensed Statements of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 98	$ 1,948	$ 8,729	$ 2,728
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives		$ (4,288)		$ (3,806)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives				$ 13
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ 62	$ 3,191	$ 734	$ 2,498
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Net	Interest Income (Expense), Net	Interest Income (Expense), Net	Interest Income (Expense), Net
Other comprehensive income (loss) | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ (2,673)	$ 1,627	$ 2,915	$ 1,921
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Other comprehensive income (loss) | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives				$ (6)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Cost of sales - income | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 2,771	$ 321	$ 5,814	$ 807
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold	Cost of Goods and Services Sold	Cost of Goods and Services Sold	Cost of Goods and Services Sold
Cost of sales - income | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives				$ 19
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold	Cost of Goods and Services Sold	Cost of Goods and Services Sold	Cost of Goods and Services Sold
Foreign currency gain | Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives		$ (4,288)		$ (3,806)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Gain (Loss), Foreign Currency Transaction, before Tax	Gain (Loss), Foreign Currency Transaction, before Tax	Gain (Loss), Foreign Currency Transaction, before Tax	Gain (Loss), Foreign Currency Transaction, before Tax
Interest expense, net | Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ 62	$ 3,191	$ 734	$ 2,498
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Net	Interest Income (Expense), Net	Interest Income (Expense), Net	Interest Income (Expense), Net

Financial Instruments - Summary

Financial Instruments - Summary of Receivables Factored and Availability Under Receivables Factoring Agreements (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Receivables factored and outstanding	$ 22,372	$ 19,108
Amount available under the credit limit	1,169	5,034
Collective factoring limit	$ 23,541	$ 24,142

Financial Instruments - Summa_2

Financial Instruments - Summary of Trade Receivables Sold and Factoring Fees Incurred (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	[1]	Sep. 30, 2023	Sep. 30, 2022	[1]
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Trade receivables sold	$ 35,115	$ 23,706		$ 111,915	$ 23,706
Factoring fees incurred	$ 221	$ 64		$ 588	$ 64
[1] Represents trade receivables sold and factoring fees incurred since the acquisition of Alfmeier (acquired on August 1, 2022) .

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Fair Value, Recurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value	$ 0	$ 0
Financial liabilities, fair value	0	0
Fair Value, Nonrecurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value	0	0
Financial liabilities, fair value	$ 0	$ 0

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2020
Class Of Stock [Line Items]
Shares repurchased	11,101	31,094
Average cost per share	$ 56.91	$ 58.54
Remaining authorized repurchase amount	$ 98,906	$ 98,906
2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program period			3 years
Stock repurchase program expiration date			Dec. 15, 2023
Maximum | 2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program, authorized to repurchase amount			150,000

Schedule of Reclassification Ad

Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands		3 Months Ended								9 Months Ended
		Sep. 30, 2023		Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022		Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023		Sep. 30, 2022
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		$ (37,413)			$ (46,489)	$ (68,648)			$ (36,922)	$ (46,489)		$ (36,922)
Other comprehensive (loss) income before reclassifications		(16,223)				(26,463)				(3,012)		(57,282)
Income tax effect of other comprehensive (loss) income before reclassifications		(156)				(694)				(1,949)		(1,262)
Amounts reclassified from accumulated other comprehensive loss into net income		(2,766)				(315)				(5,797)		(750)
Income taxes reclassified into net income		603				69				1,292		165
Other comprehensive loss, net of tax		(18,542)		$ (1,312)	10,388	(27,403)		$ (22,920)	(8,806)	(9,466)		(59,129)
Ending Balance		(55,955)		(37,413)		(96,051)		(68,648)		(55,955)		(96,051)
Defined Benefit Pension Plans
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		(1,059)			(1,067)	(2,837)			(2,893)	(1,067)		(2,893)
Amounts reclassified from accumulated other comprehensive loss into net income		5				6				17		76
Income taxes reclassified into net income		(1)								(5)		(14)
Other comprehensive loss, net of tax		4				6				12		62
Ending Balance		(1,055)		(1,059)		(2,831)		(2,837)		(1,055)		(2,831)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		(43,602)			(48,269)	(66,182)			(34,188)	(48,269)		(34,188)
Other comprehensive (loss) income before reclassifications		(16,321)				(28,411)				(11,741)		(60,023)
Income tax effect of other comprehensive (loss) income before reclassifications		(135)				(271)				(48)		(653)
Other comprehensive loss, net of tax		(16,456)				(28,682)				(11,789)		(60,676)
Ending Balance		(60,058)		(43,602)		(94,864)		(66,182)		(60,058)		(94,864)
Foreign Currency Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance		7,248			$ 2,847	371			154	2,847		154
Other comprehensive (loss) income before reclassifications		98				1,948				8,729		2,728
Income tax effect of other comprehensive (loss) income before reclassifications		(21)				(423)				(1,901)		(606)
Amounts reclassified from accumulated other comprehensive loss into net income		(2,771)	[1]			(321)	[2]			(5,814)	[3]	(807)	[4]
Income taxes reclassified into net income		604				69				1,297		175
Other comprehensive loss, net of tax		(2,090)				1,273				2,311		1,490
Ending Balance		$ 5,158		$ 7,248		$ 1,644		$ 371		$ 5,158		1,644
Commodity Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance									$ 5			5
Other comprehensive (loss) income before reclassifications												13
Income tax effect of other comprehensive (loss) income before reclassifications												(3)
Amounts reclassified from accumulated other comprehensive loss into net income	[4]											(19)
Income taxes reclassified into net income												4
Other comprehensive loss, net of tax												$ (5)
[1] The amounts reclassified from Accumulated other comprehensi ve loss w ere included in Cost of sales. The amounts reclassified from Accumulated other comprehe nsive loss wer e included in Cost of sales. The amounts reclassified from Accumulated other comprehe nsive loss wer e included in Cost of sales. The amounts reclassified from Accumulated other compreh ensive loss were included in Cost of sales.

Income Taxes - Summary of Provi

Income Taxes - Summary of Provision for Income Taxes and Corresponding Effective Tax Rate (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 6,908	$ 5,784	$ 15,478	$ 13,998
Earnings before income tax	$ 22,752	$ 15,611	$ 37,734	$ 42,644
Effective tax rate	30.40%	37.10%	41%	32.80%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income tax expense	$ 6,908	$ 5,784	$ 15,478	$ 13,998
Earnings before income tax	$ 22,752	$ 15,611	$ 37,734	$ 42,644
Effective tax rate	30.40%	37.10%	41%	32.80%
Impairment of goodwill			$ 19,509
Impairment loss with tax benefit			$ 2,255
U.S. federal statutory rate	21%	21%	21%	21%

Segment Reporting - Segment Inf

Segment Reporting - Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Product revenues	$ 366,195	$ 332,962	$ 1,102,143	$ 861,334
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 12,454	$ 11,836	$ 38,531	$ 30,470
Operating income	23,741	22,821	45,736	44,747
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues	$ 354,782	$ 322,555	$ 1,069,007	$ 829,570
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 11,399	$ 10,499	$ 34,910	$ 27,333
Operating income	41,690	43,067	126,630	98,367
Medical Segments
Segment Reporting Information [Line Items]
Product revenues	$ 11,413	$ 10,407	$ 33,136	$ 31,764
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 882	$ 1,035	$ 2,756	$ 2,224
Operating income	$ (805)	$ (2,232)	$ (21,838)	$ (3,264)
Corporate Segments
Segment Reporting Information [Line Items]
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Depreciation and amortization	$ 173	$ 302	$ 865	$ 913
Operating income	$ (17,144)	$ (18,014)	$ (59,056)	$ (50,356)

Segment Reporting - Segment I_2

Segment Reporting - Segment Information About Reported Segment Product Revenues by Product Category (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Product revenues		$ 366,195	$ 332,962	$ 1,102,143	$ 861,334
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues		354,782	322,555	1,069,007	829,570
Automotive Segments | Climate Control Seat
Segment Reporting Information [Line Items]
Product revenues		124,905	112,059	360,868	311,281
Automotive Segments | Seat Heaters
Segment Reporting Information [Line Items]
Product revenues		77,238	75,568	231,132	210,367
Automotive Segments | Steering Wheel Heaters
Segment Reporting Information [Line Items]
Product revenues		39,861	31,482	115,166	89,169
Automotive Segments | Lumbar and Massage Comfort Solutions
Segment Reporting Information [Line Items]
Product revenues	[1]	33,260	22,740	109,602	22,740
Automotive Segments | Valve System
Segment Reporting Information [Line Items]
Product revenues	[1]	27,830	18,542	82,516	18,542
Automotive Segments | Automotive Cables
Segment Reporting Information [Line Items]
Product revenues		19,668	18,338	60,131	59,662
Automotive Segments | Battery Performance Solutions
Segment Reporting Information [Line Items]
Product revenues		17,242	20,331	57,138	55,395
Automotive Segments | Electronics
Segment Reporting Information [Line Items]
Product revenues		10,163	12,083	30,456	33,190
Automotive Segments | Other Automotive
Segment Reporting Information [Line Items]
Product revenues		4,615	11,412	21,998	29,224
Industrial Segments | Medical Segments
Segment Reporting Information [Line Items]
Product revenues	[2]	$ 11,413	$ 10,407	$ 33,136	$ 31,764
[1] Represents Product revenues from Alfmeier (acquired on August 1, 2022) - (see Note 2) Includes Product revenues of $ 1,988 and $ 4,939 for the three and nine months ended September 30, 2023 , respectively, and $ 1,234 for the three and nine months ended September 30, 2022 from Dacheng (acquired on July 13, 2022) - (see Note 2)

Segment Reporting - Segment I_3

Segment Reporting - Segment Information About Reported Segment Product Revenues by Product Category (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Product revenues	$ 366,195	$ 332,962	$ 1,102,143	$ 861,334
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues	354,782	322,555	1,069,007	829,570
Medical Segments
Segment Reporting Information [Line Items]
Product revenues	11,413	10,407	33,136	31,764
Medical Segments | Dacheng
Segment Reporting Information [Line Items]
Product revenues	$ 1,988	$ 1,234	$ 4,939	$ 1,234

Segment Reporting - Product Rev

Segment Reporting - Product Revenues Information by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Product revenues	$ 366,195	$ 332,962	$ 1,102,143	$ 861,334
Revenue, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
United States
Segment Reporting Information [Line Items]
Product revenues	$ 134,588	$ 131,021	$ 414,359	$ 337,759
China
Segment Reporting Information [Line Items]
Product revenues	61,004	57,439	161,530	127,183
South Korea
Segment Reporting Information [Line Items]
Product revenues	27,369	22,751	86,102	67,632
Germany
Segment Reporting Information [Line Items]
Product revenues	24,456	19,454	77,007	54,805
Czech Republic
Segment Reporting Information [Line Items]
Product revenues	16,684	13,247	51,706	35,630
Japan
Segment Reporting Information [Line Items]
Product revenues	16,906	17,603	44,995	42,305
Romania
Segment Reporting Information [Line Items]
Product revenues	13,828	11,592	39,797	35,866
Slovakia
Segment Reporting Information [Line Items]
Product revenues	10,946	8,109	35,254	25,755
Finland
Segment Reporting Information [Line Items]
Product revenues	8,286	9,757	29,558	26,244
Mexico
Segment Reporting Information [Line Items]
Product revenues	15,251	7,062	34,701	16,171
Other
Segment Reporting Information [Line Items]
Product revenues	36,877	34,927	127,134	91,984
Non U.S.
Segment Reporting Information [Line Items]
Product revenues	$ 231,607	$ 201,941	$ 687,784	$ 523,575